SWTX Quote, Financials, Valuation and Earnings

Edgewise Therapeutics has a net margin of -108.58% compared to SpringWorks Therapeutics's net margin of --. SpringWorks Therapeutics's return on equity of -51.38% beat Edgewise Therapeutics's return on equity of --.

SpringWorks Therapeutics has a consensus price target of --, signalling upside risk potential of 91.2%. On the other hand Edgewise Therapeutics has an analysts' consensus of $49.43 which suggests that it could grow by 60.8%. Given that SpringWorks Therapeutics has higher upside potential than Edgewise Therapeutics, analysts believe SpringWorks Therapeutics is more attractive than Edgewise Therapeutics.

SpringWorks Therapeutics has a beta of 0.862, which suggesting that the stock is 13.8% less volatile than S&P 500. In comparison Edgewise Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edgewise Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. Edgewise Therapeutics pays out -- of its earnings as a dividend.

SpringWorks Therapeutics quarterly revenues are $49.3M, which are larger than Edgewise Therapeutics quarterly revenues of --. SpringWorks Therapeutics's net income of -$53.5M is lower than Edgewise Therapeutics's net income of -$34.1M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while Edgewise Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 18.90x versus -- for Edgewise Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -108.58% compared to SpringWorks Therapeutics's net margin of -49.65%. SpringWorks Therapeutics's return on equity of -51.38% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

SpringWorks Therapeutics has a consensus price target of --, signalling upside risk potential of 91.2%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 602.96%. Given that NovaBay Pharmaceuticals has higher upside potential than SpringWorks Therapeutics, analysts believe NovaBay Pharmaceuticals is more attractive than SpringWorks Therapeutics.

SpringWorks Therapeutics has a beta of 0.862, which suggesting that the stock is 13.8% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

SpringWorks Therapeutics quarterly revenues are $49.3M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. SpringWorks Therapeutics's net income of -$53.5M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 18.90x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

PTC Therapeutics has a net margin of -108.58% compared to SpringWorks Therapeutics's net margin of -54.2%. SpringWorks Therapeutics's return on equity of -51.38% beat PTC Therapeutics's return on equity of --.

SpringWorks Therapeutics has a consensus price target of --, signalling upside risk potential of 91.2%. On the other hand PTC Therapeutics has an analysts' consensus of -- which suggests that it could grow by 26.98%. Given that SpringWorks Therapeutics has higher upside potential than PTC Therapeutics, analysts believe SpringWorks Therapeutics is more attractive than PTC Therapeutics.

SpringWorks Therapeutics has a beta of 0.862, which suggesting that the stock is 13.8% less volatile than S&P 500. In comparison PTC Therapeutics has a beta of 0.629, suggesting its less volatile than the S&P 500 by 37.101%.

SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. PTC Therapeutics pays out -- of its earnings as a dividend.

SpringWorks Therapeutics quarterly revenues are $49.3M, which are smaller than PTC Therapeutics quarterly revenues of $196.8M. SpringWorks Therapeutics's net income of -$53.5M is higher than PTC Therapeutics's net income of -$106.7M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while PTC Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 18.90x versus 3.92x for PTC Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -108.58% compared to SpringWorks Therapeutics's net margin of 37.71%. SpringWorks Therapeutics's return on equity of -51.38% beat Vertex Pharmaceuticals's return on equity of -2.89%.

SpringWorks Therapeutics has a consensus price target of --, signalling upside risk potential of 91.2%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $498.37 which suggests that it could grow by 25.42%. Given that SpringWorks Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe SpringWorks Therapeutics is more attractive than Vertex Pharmaceuticals.

SpringWorks Therapeutics has a beta of 0.862, which suggesting that the stock is 13.8% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.364, suggesting its less volatile than the S&P 500 by 63.631%.

SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

SpringWorks Therapeutics quarterly revenues are $49.3M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. SpringWorks Therapeutics's net income of -$53.5M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 25.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 18.90x versus 9.73x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.